Cabaletta Bio, Inc.
corporate_fare Company Profile
Cabaletta Bio, Inc. (NASDAQ:CABA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for CABA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-14, rated 9/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for CABA spans 8-K, 10-Q, DEFA14A, 424B5.
Recent high-impact activity:
- Cabaletta Bio Secures $128.2M from Warrant Exercises, Addressing Going Concern
- Cabaletta Bio Q2 2026: $51M Net Loss, Going Concern Warning Despite $225M Cash
- Cabaletta Bio Reports Q2 2026 Results, Cash Runway to Mid-2027, and Key Clinical Milestones
- Cabaletta Bio Posts $51M Q2 Loss, Cash Runway to Mid-2027; Myositis Data Mid-2027
- Stockholders Approve Doubling Authorized Shares to 600 Million
Financial Snapshot
Short Interest & Short Volume
5.20 days to coverFINRA reported short interest of 33,325,453 shares in CABA as of the September 15, 2026 settlement, a 19.6% decrease from the prior period — about 5.2 days to cover at its recent average daily volume. On October 2, 2026, 54.3% of CABA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for CABA, detected from its recent SEC filings · based on capital-structure filings through 2026-05-14.
Public Offering Completed · Significant Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →